The New Wave of Peptides Everyone Will Be Talking About

If you thought the first GLP-1 compounds were the whole story, buckle up. A new generation of peptides is coming through clinical trials right now, and some of the numbers are genuinely jaw-dropping. None of these are on our protocol pages yet — so here's your first look at the names you'll be hearing everywhere soon.

Amycretin: two signals in one molecule

Amycretin is a single peptide that switches on two appetite systems at once: the GLP-1 receptor and the amylin receptor. In a 36-week trial, the highest dose group lost an average of 24.3% of their body weight, against 1.1% on placebo. That's a number that would have sounded like science fiction ten years ago — and it came from one molecule doing the job of two.

Eloralintide: the amylin comeback

Amylin is the quiet partner hormone to insulin, and researchers have chased it for decades. Eloralintide is a selective amylin receptor agonist, and in a 48-week phase 2 trial published in The Lancet, the 9 mg group lost around 20% of body weight on average, compared with 0.4% on placebo. A whole new class, not just a tweak to an old one — that's why the field is excited.

Pemvidutide: the liver angle

Pemvidutide pairs GLP-1 with glucagon receptor activity, a combination researchers are especially interested in for liver fat as well as weight. In its 48-week MOMENTUM trial, the 2.4 mg group lost 15.6% of body weight on average, and more than 30% of people in that group lost at least a fifth of their weight.

Why this moment is so exciting

Every one of these compounds goes after a different combination of hormone signals. Instead of one blockbuster, we're seeing a whole toolbox: amylin-only, GLP-1 plus amylin, GLP-1 plus glucagon, and triple agonists. The next few years of trials will show which combinations work best, for whom, and with which side effects.

The honest bit

These results come from controlled trials with medical supervision, and nausea and fatigue were common, especially at higher doses. None of these compounds is approved yet. Exciting trial numbers are a reason to follow the science closely — not a reason to try something outside a trial.

Keep exploring

Want to see how the newer compounds stack up against the ones you already know? Compare Retatrutide, Tirzepatide and Semaglutide, look up any compound in our protocol A–Z, or take the quiz to get a reading list built around what you're curious about. And if you know someone following the weight-loss science, send them this — they'll want to know these names.